What does Lantheus do?

Lantheus makes products that help doctors see and treat disease inside the body, mainly heart conditions and cancer. Its best-known products include PYLARIFY, a PET scan agent that helps find prostate cancer, and DEFINITY, which makes heart ultrasound images clearer. It also sells AI software that analyzes scans and is developing radioactive drugs that target and treat tumors.

What is Lantheus's fair value?

On an owner-earnings DCF, Lantheus's most-likely fair value is about $126, versus a recent price near $100. A margin-of-safety estimate, not a price target. Analysis, not advice.

Healthcare · Drug Manufacturers - Specialty & Generic · LNTH

What Lantheus Does & How It Makes Money (LNTH)

Updated October 2026 · reflects Lantheus's latest reported financials

Maker of medical imaging agents and radiopharmaceuticals for heart and cancer. It earns revenue by manufacturing and selling diagnostic imaging agents, nuclear medicine products and related AI software to hospitals, imaging centers and clinicians.

Lantheus's story, moat and numbers — in a 3-minute visual book.

Explore Lantheus on TacticScale →

How Lantheus makes money

It earns revenue by manufacturing and selling diagnostic imaging agents, nuclear medicine products and related AI software to hospitals, imaging centers and clinicians. It also partners with companies such as GE Healthcare, Curium and Regeneron to develop and commercialize its products.

What Lantheus does

Lantheus Holdings, founded in 1956 and based in Bedford, Massachusetts, develops, manufactures and sells diagnostic and therapeutic products for heart disease, cancer and other conditions. Its commercial portfolio includes PYLARIFY, an F 18 PSMA-targeted PET imaging agent for prostate cancer; DEFINITY, an ultrasound enhancing agent for echocardiography; and established nuclear medicine products such as the TechneLite technetium generator, Cardiolite, Neurolite and Xenon-133. It also offers RELISTOR for opioid-induced constipation, plus AI imaging software including aPROMISE, PYLARIFY AI and Automated Bone Scan Index. Its pipeline focuses on radiopharmaceutical therapies and next-generation imaging. Programs include PNT2002 for metastatic castration-resistant prostate cancer, PNT2003 for SSTR-positive neuroendocrine tumors, MK-6240 for imaging Tau tangles in Alzheimer's disease, and several early-stage LNTH-series agents. Partners include GE Healthcare, Curium Pharma, POINT, Regeneron and Ratio Therapeutics.

Products & services

PYLARIFY
DEFINITY
TechneLite
Cardiolite
PYLARIFY AI
flurpiridaz

What is Lantheus worth?

On an owner-earnings DCF, Lantheus's most-likely value is about $126 versus a recent price near $100 (26% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$63) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Verdict: Fairly priced — no edge

Owner-earnings fair value · recent price ≈ $100

Fair value (most likely)

$126

Range

$86–$242

No-growth floor

$63

Price

~$100

Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.

Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →

Sector Healthcare Industry Drug Manufacturers - Specialty & Generic HQ United States Ticker LNTH Official site

Related companies

GE HealthCare Technologies (GEHC) · RadNet (RDNT) · Labcorp (LH)

Understand Lantheus in 3 minutes →